# Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

> **NCT04684446** · PHASE1,PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** AZD1222
- **BIOLOGICAL:** rAd26-S

## Key facts

- **NCT ID:** NCT04684446
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2021-11-26
- **Final completion:** 2022-03-29
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-06-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04684446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04684446, "Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04684446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*